Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 23(15)2022 Aug 02.
Article in English | MEDLINE | ID: mdl-35955717

ABSTRACT

Methylphenidate (MPH) is among the main drugs prescribed to treat patients with attention-deficit and hyperactivity disease (ADHD). MPH blocks both the norepinephrine and dopamine reuptake transporters (NET and DAT, respectively). Our study was aimed at further understanding the mechanisms by which MPH could modulate neurotransmitter efflux, using ex vivo radiolabelled neurotransmitter assays isolated from rats. Here, we observed significant dopamine and norepinephrine efflux from the prefrontal cortex (PFC) after MPH (100 µM) exposure. Efflux was mediated by both dopamine and norepinephrine terminals. In the striatum, MPH (100 µM) triggered dopamine efflux through both sodium- and vesicular-dependent mechanisms. Chronic MPH exposure (4 mg/kg/day/animal, voluntary oral intake) for 15 days, followed by a 28-day washout period, increased the firing rate of PFC pyramidal neurons, assessed by in vivo extracellular single-cell electrophysiological recordings, without altering the responses to locally applied NMDA, via micro-iontophoresis. Furthermore, chronic MPH treatment resulted in decreased efficiency of extracellular dopamine to modulate NMDA-induced firing activities of medium spiny neurons in the striatum, together with lower MPH-induced (100 µM) dopamine outflow, suggesting desensitization to both dopamine and MPH in striatal regions. These results indicate that MPH can modulate neurotransmitter efflux in brain regions enriched with dopamine and/or norepinephrine terminals. Further, long-lasting alterations of striatal and prefrontal neurotransmission were observed, even after extensive washout periods. Further studies will be needed to understand the clinical implications of these findings.


Subject(s)
Central Nervous System Stimulants , Methylphenidate , Neurochemistry , Animals , Central Nervous System Stimulants/pharmacology , Central Nervous System Stimulants/therapeutic use , Dopamine , Dopamine Plasma Membrane Transport Proteins/metabolism , Electrophysiology , Methylphenidate/pharmacology , Methylphenidate/therapeutic use , N-Methylaspartate , Norepinephrine , Prefrontal Cortex/metabolism , Rats
3.
Bioorg Chem ; 85: 152-158, 2019 04.
Article in English | MEDLINE | ID: mdl-30612081

ABSTRACT

Aggregation/misfolding of α-synuclein and ßA4 proteins cause neuronal cell death (NCD) associated with Parkinson's and Alzheimer's disease. It has been suggested that a heat shock protein-90 (Hsp90) inhibitor can prevent NCD by activating the heat shock transcription factor-1 which, in turn, upregulates molecular chaperones such as Hsp70 that targets aggregated/misfolded proteins for refolding/degradation. We have isolated radicicol, an Hsp90 inhibitor, from a fungus occurring in the crevices of marble rocks of Central India. Radicicol, which was found to be a strong antioxidant, was tested for its ability to rescue yeast cells from death induced by expression of wild-type α-synuclein, its more toxic A53T mutant, and ßA4. It effectively overcomes wild-type/mutant α-synuclein mediated yeast cell death, concomitantly diminishes ROS levels, reverses mitochondrial dysfunction and prevents nuclear DNA-fragmentation, a hallmark of apoptosis. Surprisingly however, radicicol is unable to rescue yeast cells from death triggered by expression of secreted ßA4. Moreover, although radicicol acts as an antioxidant it fails to prevent yeast cell death inflicted by the proapoptotic protein, Bax. Our results indicate that radicicol specifically targets aggregated/misfolded α-synuclein's toxicity and opens up the possibility of using multiple yeast assays to screen natural product libraries for compounds that would unambiguously target α-synuclein aggregation/misfolding.


Subject(s)
Amyloid beta-Peptides/metabolism , Apoptosis/drug effects , Free Radical Scavengers/pharmacology , Macrolides/pharmacology , alpha-Synuclein/metabolism , bcl-2-Associated X Protein/metabolism , Amyloid beta-Peptides/genetics , Free Radical Scavengers/isolation & purification , Free Radical Scavengers/metabolism , Humans , Macrolides/isolation & purification , Macrolides/metabolism , Membrane Potential, Mitochondrial/drug effects , Mitochondria/metabolism , Molecular Docking Simulation , Mutation , Protein Binding , Reactive Oxygen Species/metabolism , Saccharomyces cerevisiae/genetics , Sordariales/chemistry , alpha-Synuclein/genetics , bcl-2-Associated X Protein/genetics
4.
Bioorg Med Chem Lett ; 29(3): 454-460, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30579794

ABSTRACT

Herein, we have identified yeast Sec22p (ySec22p), a SNARE protein essential for endoplasmic reticulum to Golgi trafficking, as a suppressor of Bax-induced yeast apoptosis and corroborated published observations that ySec22p suppresses α-synuclein's toxicity in yeast. It has been suggested that compounds which enhance expression, in neurons, of human homologues of ySec22p (Sec22Bp/Sec22p/Sec22A) would prevent synucleinopathies, such as Parkinson's disease. With the aim of finding a small molecule that would mimic ySec22p, a library of natural products consisting of 394-compounds was screened using yeast cells that express either human α-synuclein or human Bax. The antioxidant aegeline, an alkaloid-amide occurring in the leaves of the plant Aegle marmelos Correa, was the only molecule that overcame apoptosis induced by both α-synuclein and Bax in yeast. Besides, aegeline also prevented growth block in cells expressing the more toxic A53T α-synuclein mutant. Restoration of cell growth occurred through inhibition of increased ROS levels, mitochondrial membrane potential loss and nuclear DNA fragmentation, characteristics of apoptosis manifested in α-synuclein or Bax-expressing cells. These results highlight the importance of yeast systems to identify rapidly molecules that may prevent the onset of apoptosis that occurs in Parkinson's disease.


Subject(s)
Aegle/chemistry , Amides/pharmacology , Antioxidants/pharmacology , Biological Products/pharmacology , R-SNARE Proteins/antagonists & inhibitors , Saccharomyces cerevisiae Proteins/antagonists & inhibitors , Saccharomyces cerevisiae/drug effects , Amides/chemistry , Amides/isolation & purification , Antioxidants/chemistry , Antioxidants/isolation & purification , Apoptosis/drug effects , Biological Products/chemistry , Biological Products/isolation & purification , Dose-Response Relationship, Drug , Molecular Structure , R-SNARE Proteins/metabolism , Saccharomyces cerevisiae/chemistry , Saccharomyces cerevisiae/cytology , Saccharomyces cerevisiae Proteins/metabolism , Structure-Activity Relationship , alpha-Synuclein/metabolism , bcl-2-Associated X Protein/metabolism
5.
Eur J Pharm Sci ; 128: 118-127, 2019 Feb 01.
Article in English | MEDLINE | ID: mdl-30502452

ABSTRACT

Aggregated Aß peptides which cause amyloid deposits, a characteristic of Alzheimer's disease (AD), activate a stress response in the endoplasmic reticulum (ER), known as the unfolded protein response, UPRER. Nascent UPRER induction helps in reducing ER stress by eliminating accumulated misfolded/aggregated secretory proteins. However, prolonged UPRER induction may trigger apoptosis. Here we show that, when expressed in yeast with an NH2-terminal secretory signal sequence (ss), the 42-amino acid human Aß42 (h_Aß42), but not the mouse/ratAß42 (m_Aß42) which reportedly does not misfold/aggregate, induces UPRER as monitored via an eGFP reporter. We also show that expression of ss-h_Aß42, not ss-m_Aß42, blocks yeast cell growth, with cells expressing ss-h_Aß42 manifesting distinctive features of apoptosis such as loss of mitochondrial membrane potential, increase in ROS levels and DNA fragmentation. Screening for suppressors of ss-h_Aß42-activated UPRER-eGFP induction, in a computationally-designed 29-compound methoxy-stilbene library, revealed three compounds that reduce >95% of UPRER-eGFP induction at 5 µM concentration, with EC50 values of 40-50 nM. Surprisingly, the compounds also rescue yeast cells from ss-h_Aß42-mediated apoptosis, with EC50-s of 50-60 nM. These results provide direct evidence, probably for the first time, that there is a direct correlation between deactivation of UPRER and attenuation of apoptosis.


Subject(s)
Amyloid beta-Peptides/antagonists & inhibitors , Apoptosis/physiology , Peptide Fragments/antagonists & inhibitors , Saccharomyces cerevisiae/drug effects , Stilbenes/pharmacology , Amyloid beta-Peptides/metabolism , Animals , Endoplasmic Reticulum , Gene Expression Regulation, Fungal/drug effects , Mice , Molecular Structure , Peptide Fragments/metabolism , Rats , Reactive Oxygen Species , Saccharomyces cerevisiae/metabolism , Stilbenes/chemical synthesis , Stilbenes/chemistry , Structure-Activity Relationship , Unfolded Protein Response
6.
ACS Omega ; 3(8): 9513-9532, 2018 Aug 31.
Article in English | MEDLINE | ID: mdl-31459084

ABSTRACT

The overexpression of α-synuclein (α-syn) and its aggregation is the hallmark of Parkinson's disease. The α-syn aggregation results in the formation of Lewy bodies that causes neuronal cell death. Therefore, the small molecules that can protect neuronal cells from α-syn toxicity or inhibit the aggregation of α-syn could emerge as anti-Parkinson agents. Herein, a library of methoxy-stilbenes was screened for their ability to restore the cell growth from α-syn toxicity, using a yeast strain that stably expresses two copies of a chromosomally integrated human α-syn gene. Tetramethoxy-stilbene 4s, a nonantioxidant, was the most capable of restoring cell growth. It also rescues the more toxic cells that bear three copies of wild-type or A53T-mutant α-syn, from cell growth block. Its EC50 values for growth restoration of the 2-copy wild-type and the 3-copy mutant α-syn strains are 0.95 and 0.35 µM, respectively. Stilbene 4s mitigates mitochondrial membrane potential loss, negates ROS production, and prevents nuclear DNA-fragmentation, all hallmarks of apoptosis. However, 4s does not rescue cells from the death-inducing effects of Bax and ßA4, which suggest that 4s specifically inhibits α-syn-mediated toxicity in the yeast. Our results signify that simultaneous use of multiple yeast-cell-based screens can facilitate revelation of compounds that may have the potential for further investigation as anti-Parkinson's agents.

SELECTION OF CITATIONS
SEARCH DETAIL
...